SCM
WHWK

Soleus Capital Management’s Whitehawk Therapeutics WHWK Stock Holding History

Soleus Capital Management’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-333,227
Closed -$1.05M – 98
2024
Q4 		$1.05M Hold
333,227
– – 0.07% 73
2024
Q3 		$686K Hold
333,227
– – 0.05% 85
2024
Q2 		$487K Buy
+333,227
New +$618K 0.04% 88
2023
Q4 		– Sell
-333,227
Closed -$1.61M – 105
2023
Q3 		$1.61M Hold
333,227
– – 0.15% 72
2023
Q2 		$2.28M Buy
+333,227
New +$2.59M 0.25% 71

Other funds holding WHWK

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
YF
Yu Fan $97M AUM 57.2% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Soleus Capital Management's WHWK Position: Q1 2025 in Review

Soleus Capital Management sold out of Whitehawk Therapeutics (WHWK) in Q1 2025, closing a stake of 333,227 shares — an estimated $1.05M sold.

Soleus Capital Management first reported a position in WHWK in Q2 2023 and held it in 5 quarters. The position peaked at $2.28M in Q2 2023. 50 funds tracked by Wall St. Rank hold WHWK as of Q1 2025.

  • Soleus Capital Management reported no remaining Whitehawk Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Soleus Capital Management sold 333,227 Whitehawk Therapeutics shares in Q1 2025, an estimated $1.05M.
  • Soleus Capital Management first reported a position in Whitehawk Therapeutics in Q2 2023 and held it in 5 quarters.
  • Soleus Capital Management's Whitehawk Therapeutics position peaked at $2.28M in Q2 2023.
  • 50 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q1 2025.

Based on Soleus Capital Management's 13F filing for Q1 2025, filed 15 May 2025.